Internal Medicine, Sinai Grace Hospital, Detroit, Michigan, USA
Internal Medicine, Sinai Grace Hospital, Detroit, Michigan, USA.
BMJ Case Rep. 2021 Apr 20;14(4):e240925. doi: 10.1136/bcr-2020-240925.
Burkitt lymphoma (BL) is a rare, mature, fast-growing and highly aggressive B-cell neoplasm. It has a high-proliferation rate with distinctive genetic changes in the C-MYC oncogene. Treatment usually requires intense and frequent chemotherapy regimens with central nervous system prophylaxis as the usual regimens used for other non-Hodgkin's lymphoma yield poor survival in BL. This report discusses a patient who was diagnosed with a stage II, high-grade BL who received one cycle of intense chemotherapy and refused further treatment. That patient remained in complete remission in his last follow-up; 7 years from diagnosis without requiring other therapies for his lymphoma.
伯基特淋巴瘤(BL)是一种罕见的、成熟的、快速生长的、高度侵袭性的 B 细胞肿瘤。它具有高增殖率和 C-MYC 癌基因的特征性遗传改变。治疗通常需要强烈和频繁的化疗方案,并进行中枢神经系统预防,因为用于其他非霍奇金淋巴瘤的常规方案在 BL 中的生存率较差。本报告讨论了一名诊断为 II 期高级别 BL 的患者,他接受了一个周期的强化化疗后拒绝进一步治疗。该患者在最后一次随访时仍处于完全缓解状态;从诊断到现在已经 7 年,他的淋巴瘤没有需要其他治疗。